Catherine Schulte
Stock Analyst at Baird
(3.39)
# 964
Out of 5,241 analysts
138
Total ratings
47.41%
Success rate
3.81%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTD Mettler-Toledo International | Maintains: Neutral | $1,445 → $1,194 | $1,074.84 | +11.09% | 11 | May 11, 2026 | |
| QGEN Qiagen | Upgrades: Outperform | $53 → $43 | $33.78 | +27.29% | 5 | Apr 29, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $653 → $639 | $442.00 | +44.57% | 29 | Apr 24, 2026 | |
| DHR Danaher | Maintains: Outperform | $249 → $245 | $163.86 | +49.52% | 13 | Apr 22, 2026 | |
| CAI Caris Life Sciences | Maintains: Outperform | $26 → $28 | $15.10 | +85.43% | 2 | Feb 27, 2026 | |
| GRAL GRAIL | Maintains: Outperform | $113 → $82 | $60.71 | +35.07% | 2 | Feb 20, 2026 | |
| TEM Tempus AI | Initiates: Outperform | $59 | $43.62 | +35.26% | 1 | Feb 17, 2026 | |
| GH Guardant Health | Initiates: Outperform | $120 | $95.66 | +25.44% | 1 | Feb 17, 2026 | |
| A Agilent Technologies | Maintains: Outperform | $142 → $165 | $112.11 | +47.18% | 18 | Nov 25, 2025 | |
| AVTR Avantor | Maintains: Outperform | $15 → $17 | $7.60 | +123.68% | 14 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $4.08 | -50.98% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $88 → $68 | $44.43 | +53.05% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $19.32 | +96.69% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $49.79 | -33.72% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $141.51 | +98.57% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $332.19 | -34.68% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $192.54 | -89.61% | 1 | Jun 28, 2018 |
Mettler-Toledo International
May 11, 2026
Maintains: Neutral
Price Target: $1,445 → $1,194
Current: $1,074.84
Upside: +11.09%
Qiagen
Apr 29, 2026
Upgrades: Outperform
Price Target: $53 → $43
Current: $33.78
Upside: +27.29%
Thermo Fisher Scientific
Apr 24, 2026
Maintains: Outperform
Price Target: $653 → $639
Current: $442.00
Upside: +44.57%
Danaher
Apr 22, 2026
Maintains: Outperform
Price Target: $249 → $245
Current: $163.86
Upside: +49.52%
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $26 → $28
Current: $15.10
Upside: +85.43%
GRAIL
Feb 20, 2026
Maintains: Outperform
Price Target: $113 → $82
Current: $60.71
Upside: +35.07%
Tempus AI
Feb 17, 2026
Initiates: Outperform
Price Target: $59
Current: $43.62
Upside: +35.26%
Guardant Health
Feb 17, 2026
Initiates: Outperform
Price Target: $120
Current: $95.66
Upside: +25.44%
Agilent Technologies
Nov 25, 2025
Maintains: Outperform
Price Target: $142 → $165
Current: $112.11
Upside: +47.18%
Avantor
Oct 24, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $7.60
Upside: +123.68%
May 13, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $4.08
Upside: -50.98%
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $44.43
Upside: +53.05%
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $19.32
Upside: +96.69%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $49.79
Upside: -33.72%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $141.51
Upside: +98.57%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $332.19
Upside: -34.68%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $192.54
Upside: -89.61%